In a new collaboration that could transform how cancer is treated, OCCAM Immune—a Mount Sinai initiative focused on understanding the immune system’s role in disease—is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies. Under the agreement, OCCAM Immune and CRI have established a long-term plan to support ongoing immune monitoring across CRI’s clinical trials. The collaboration provides a flexible framework for launching new projects efficiently and will focus on tracking how patients’ immune systems respond to treatment, with the goal of identifying which patients are most likely to benefit from certain immunotherapies and why.

A new gene-editing method enables researchers to more easily determine whether a patient has inherited an increased risk of developing cancer - before any symptoms appear. Researchers at Rigshospitalet in Copenhagen have tested the method in a hospital setting and believe it has the potential to save lives worldwide.